banner

Posts tagged as: 505b2 back to homepage

Cellceutix Selects Dr. Reddy’s for Manufacturing of New Psoriasis Drug Cellceutix Selects Dr. Reddy’s for Manufacturing of New Psoriasis Drug(0)

Beverly, Massachusetts-based Cellceutix Corporation (OTCBB: CTIX) reported this morning that they have chosen Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) to synthesize and manufacture Prurisol, Cellceutix’s lead anti-psoriasis drug candidate.  Cellceutix will be advancing Prurisol into Phase II/III clinical trials under guidance from the Food and Drug Administration that the drug qualifies for a 505(b)(2) designation. Read More
FDA Gives Nod to Cellceutix for 505(b)(2) Eligibility for Psoriasis Drug FDA Gives Nod to Cellceutix for 505(b)(2) Eligibility for Psoriasis Drug(0)

Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports today that it has participated in a meeting with the U.S. Food and Drug Administration (“FDA”) pertaining to the Company’s psoriasis compound, Prurisol™.  As previously disclosed on April 16, 2012, the Company had Read More
Cellceutix Files Pre-IND Documentation with FDA for New Psoriasis Drug Cellceutix Files Pre-IND Documentation with FDA for New Psoriasis Drug(0)

Company Gets Started on Next Drug in Their Pipeline

Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that it has filed a pre-IND submission with the U.S. Food and Drug Administration (FDA) on Prurisol™ (also termed “KM-133″), the Company’s drug in development as a novel treatment for psoriasis. Read More

OTCBB News

Electronic Control Security Lands Prime Government Contract Electronic Control Security Lands Prime Government Contract(0)
Balqon Lithium Battery System Installed in Hybrid Yacht Balqon Lithium Battery System Installed in Hybrid Yacht(0)
Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix(0)
ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer(0)
Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump(0)
Drinks Americas Signs Sales Agreement for Marigold Craft Beer Drinks Americas Signs Sales Agreement for Marigold Craft Beer(0)
read more


Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Gateways

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories
Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.